Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.0K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

607
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
607
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

656
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
656
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

557
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
557
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.1K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.1K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.7K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Amplicon-Based Next-Generation Sequencing Testing and Immunohistochemical Staining in Detecting <i>Anaplastic Lymphoma Kinase</i> Fusion Genes in Non-Small-Cell Lung Cancer: A Large Single-Centre Cohort Study.

Cancers·2026
Same author

Critical ischemia of multiple organ systems in a patient with systemic lupus erythematosus complicated by catastrophic antiphospholipid syndrome: Potential pathogenetic role of non-inhibitory anti-ADAMTS13 autoantibodies.

Modern rheumatology case reports·2026
Same author

Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

Thoracic cancer·2026
Same author

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP.

Frontiers in immunology·2026
Same author

Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With <i>EGFR</i> Mutation (West Japan Oncology Group 11719L: ADJUST Study).

JTO clinical and research reports·2026
Same author

Rapidly progressive fibrinopurulent pleural empyema with systemic juvenile idiopathic arthritis during treatment with tocilizumab.

Rheumatology advances in practice·2026

Related Experiment Video

Updated: Feb 20, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

[Tuberculosis associated with anti-TNF therapy].

Mitsuhiro Takeno1, Shuji Murakami, Yoshiaki Ishigatsubo

  • 1Department of Internal Medicine and Clinical Immunology, Yokohama City University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 24, 2007
PubMed
Summary

Anti-TNF therapy raises tuberculosis risk, often appearing within six months. Newer immunological assays offer better screening than traditional tests for patients on anti-TNF drugs.

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.3K
A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.5K

Related Experiment Videos

Last Updated: Feb 20, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.3K
A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.5K

Area of Science:

  • Immunology
  • Infectious Diseases
  • Rheumatology

Context:

  • Anti-tumor necrosis factor (TNF) therapies are associated with an increased risk of developing tuberculosis (TB).
  • TB often manifests within six months of anti-TNF therapy initiation, suggesting reactivation of latent infection.
  • Atypical presentations like extrapulmonary and disseminated TB are common, complicating early diagnosis.

Purpose:

  • To evaluate the effectiveness of current tuberculosis screening methods before anti-TNF therapy.
  • To highlight the limitations of the tuberculin skin test (TST) in BCG-vaccinated populations or those on anti-rheumatic agents.
  • To introduce alternative immunological assays for improved tuberculosis screening and monitoring in patients undergoing anti-TNF therapy.

Summary:

  • Anti-TNF therapy significantly elevates the risk of tuberculosis, primarily through reactivation of latent infections.
  • Traditional screening methods like TST have limitations, including false positives in BCG-vaccinated individuals and false negatives with certain medications.
  • Interferon-gamma release assays (IGRAs) demonstrate higher sensitivity and specificity for detecting latent tuberculosis infection compared to TST.

Impact:

  • Improved diagnostic accuracy for tuberculosis in patients receiving anti-TNF therapy.
  • Enhanced patient safety through more effective screening and monitoring protocols.
  • Potential reduction in tuberculosis incidence and severity among individuals treated with anti-TNF agents.